Quantum computing

• [New] The overall quantum computing market is projected to grow to $1.7 B by 2026, at a CAGR of 30.2% by analysts at MarketandMarkets.
• [New] In the next decade, quantum computation will become a very disruptive technology in many areas, including in several crucial defense applications.
• [New] Rather than replacing current computer architectures, IBM is betting that quantum computers will gain traction in the coming years by taking on very specific tasks that are offloaded from a classic computing system to a quantum platform.
• [New] The RIKEN RQC-Fujitsu Collaboration Center will see the development of hardware and software technologies to realise a quantum computer with as many as 1,000 qubits and develop applications using a prototype quantum computer.
• [New] In the next 10 years, things once considered science fiction will become science fact, from augmented reality and artificial intelligence (AI) to quantum computing.
• [New] The researchers at the Wallenberg Centre for Quantum Technology, WACQT, have the goal to build a quantum computer - based on superconducting circuits - with at least 100 well-functioning qubits, performing correct calculations by 2030.
• [New] In the next two or three years companies will begin to make major changes and advances in software and software development to exploit quantum computing and speed up their workflows.
• [New] The quantum computing ecosystem in Ireland should benefit in 2022 from the rollout of a national quantum learning platform, that will be coupled to the supercomputer Kay.
• The FDA is currently weighing Rinvoq in psoriatic arthritis, a market that AbbVie also hopes to crack with Skyrizi, its IL-23 blocker currently approved in plaque psoriasis.
• Barcelona-based biopharma company Almirall and New York-based Happify Health will be working together to develop an international version of Claro, a digital treatment that addresses the mental health of psoriasis patients.
• The medical dermatology-focused pharma nabbed a recent approval in France for Ilumetri, an anti-IL - 23 p19 to treat psoriasis, with a launch expected soon.
• In a major register-based study, scientists at University of Gothenburg, Sweden, have now demonstrated a connection between inferior physical fitness in young adults and elevated risk of the autoimmune disease psoriasis.
• The EU market has seen eight biosimilar products of adalimumab, while the US will be able to commercialize their first one only in 2023 due to the bio-originator' s US market exclusivity.
• BMS is awaiting additional Phase III data for its oral psoriasis drug BMS-986165, which could be a game-changer, in terms of convenience, for patients with moderate-to-severe disease.
• After just two years on the market, psoriasis med Skyrizi could reach more than $1 billion in global sales in 2021, driven by booming scripts and lucrative indications in its pipeline.
• AbbVie can take hope in the launch of psoriasis med Skyrizi, which nabbed $91 million worldwide in the third quarter.
• A San Diego-based medical-device maker has landed a Series A investment of $18 million that will help to further commercialize its connected, handheld phototherapy device that is FDA-approved for patients with psoriasis and other skin conditions.
• Otezla is Celgene's marketed oral drug for psoriasis and psoriatic arthritis that had sales of $1.6 billion in 2018, and that number is rising to $2.5 billion in 2023.
• Stelara might be a good, more protected market as not all Crohn's and psoriasis patients will use anti-TNF products, which might protect volume and margins.
• AbbVie's hoping to grab market share with that drug ahead of Humira's biosim threat in 2023, when several players can launch under individual agreements with AbbVie.
• The rheumatoid arthritis and psoriasis markets are largely mature, but could see around $5 billion to $10 billion in expansion.
• Cosentyx is expected to be Novartis' top-selling drug during 2019, with robust growth in all three approved indications: plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.

Last updated: 18 April 2021